Targeted therapies in colorectal cancer—an integrative view by PPPM

Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.

(2017) C. Bernaards et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).

(2017) E. Mrozek et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

(2017) H. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

(2015) Susan D. Richman et al.   Analytical Cellular Pathology

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients

(2012) A Abajo et al.   BRITISH JOURNAL OF CANCER

Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection

(2012) A Dewdney et al.   BRITISH JOURNAL OF CANCER

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

(2012) Arjun Sood et al.   Clinical Colorectal Cancer

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study

(2012) Fairooz F. Kabbinavar et al.   EUROPEAN JOURNAL OF CANCER

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

(2012) Mai Yamauchi et al.   GUT

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu

(2012) Sebastian Stintzing et al.   INTERNATIONAL JOURNAL OF CANCER

Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

(2012) Natsuko Hori et al.   International Journal of Clinical Oncology

Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer

(2012) Mariangela Manzoni et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

(2012) David J McBride et al.   JOURNAL OF PATHOLOGY

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

(2012) Paola Ulivi et al.   Journal of Translational Medicine

NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy

(2012) Fiona Rinaldi et al.   LANCET ONCOLOGY

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

(2012) Diether Lambrechts et al.   LANCET ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

(2012) Zhong-Zhen Guan et al.   Chinese Journal of Cancer

Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments

(2012) Carl-Magnus Clausson et al.   EPMA Journal

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab †

(2011) D. Malka et al.   ANNALS OF ONCOLOGY

Molecular Genetics of Colorectal Cancer

(2011) Eric R. Fearon   Annual Review of Pathology-Mechanisms of Disease

Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy

(2011) Allie H Grossmann et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Bevacizumab-Induced Hypertension

(2011) Kostas N. Syrigos et al.   BIODRUGS

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

(2011) Laetitia Dahan et al.   BMC CANCER

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6

(2011) J P B O'Connor et al.   BRITISH JOURNAL OF CANCER

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

(2011) A Ålgars et al.   BRITISH JOURNAL OF CANCER

Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab

(2011) Satoshi Matsusaka et al.   CANCER

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

(2011) Fotios Loupakis et al.   CANCER

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

(2011) Claire L. Vale et al.   CANCER TREATMENT REVIEWS

KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective

(2011) P. R. Blank et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions

(2011) Muhammad Wasif Saif et al.   Clinical Colorectal Cancer

The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status

(2011) Edith P. Mitchell et al.   Clinical Colorectal Cancer

The Continuation of Bevacizumab Following Disease Progression in Patients with Metastatic Colorectal Cancer Offers a Survival Benefit

(2011) Georgios F. Samelis et al.   HEPATO-GASTROENTEROLOGY

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

(2011) Arthi Vijayaraghavan et al.   INTERNATIONAL JOURNAL OF CANCER

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

(2011) Satu Oltedal et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

(2011) Myoung Joo Kang et al.   INVESTIGATIONAL NEW DRUGS

Genetics, Cytogenetics, and Epigenetics of Colorectal Cancer

(2011) Lucia Migliore et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

(2011) Hiromichi Ebi et al.   JOURNAL OF CLINICAL INVESTIGATION

Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features

(2011) Inti Zlobec et al.   JOURNAL OF PATHOLOGY

Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies

(2011) Rodrigo Leite de Oliveira et al.   MOLECULAR ASPECTS OF MEDICINE

Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis

(2011) Alyssa L. Kennedy et al.   MOLECULAR CELL

Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety

(2011) M. Bonifazi et al.   ONCOLOGIST

Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy

(2011) C. Pinto et al.   ONCOLOGIST

Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases

(2011) Hans Bösmüller et al.   PATHOLOGY RESEARCH AND PRACTICE

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

(2011) A K Koutras et al.   PHARMACOGENOMICS JOURNAL

Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer

(2011) Liora Farber et al.   VIRCHOWS ARCHIV

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

(2011) Nikhil Wagle et al.   Cancer Discovery

Microsatellite instability in the management of colorectal cancer

(2011) Maria S Pino et al.   Expert Review of Gastroenterology & Hepatology

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

(2010) M. Ronzoni et al.   ANNALS OF ONCOLOGY

The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab

(2010) L. H. J. Simkens et al.   ANNALS OF ONCOLOGY

Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer

(2010) Satoshi Matsusaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

(2010) M. Janakiraman et al.   CANCER RESEARCH

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer

(2010) Jan Pander et al.   EUROPEAN JOURNAL OF CANCER

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

(2010) Martin Zweifel et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer

(2010) Rodrigo Jover et al.   GASTROENTEROLOGY

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer

(2010) Geraldine Perkins et al.   INTERNATIONAL JOURNAL OF CANCER

Unerwünschte dermatologische Wirkungen bei therapeutischer Inhibition des VEGF-Signalweges

(2010) Gottfried Wozel et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

(2010) Suzanne E. Dahlberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics of recurrence after curative resection for T1 colorectal cancer: Japanese multicenter study

(2010) Hirotoshi Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

(2010) Adrian M Jubb et al.   LANCET ONCOLOGY

BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis

(2010) Chen Mao et al.   MOLECULAR BIOLOGY REPORTS

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

(2010) D. G. Duda et al.   ONCOLOGIST

“First do no harm” and the importance of prediction in oncology

(2010) Dainius Characiejus et al.   EPMA Journal

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma

(2009) P. Bono et al.   ANNALS OF ONCOLOGY

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer

(2009) K. -L. Garm Spindler et al.   ANNALS OF ONCOLOGY

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

(2009) J Souglakos et al.   BRITISH JOURNAL OF CANCER

PTEN status in advanced colorectal cancer treated with cetuximab

(2009) F V Negri et al.   BRITISH JOURNAL OF CANCER

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity andKRASstatus in patients receiving panitumumab monotherapy

(2009) Marc Peeters et al.   CANCER

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

(2009) H. Prenen et al.   CLINICAL CANCER RESEARCH

Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function

(2009) Wolfgang Lieb et al.   EUROPEAN HEART JOURNAL

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS Mutation

(2009) Wilbur A. Franklin et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

(2009) Andrew X Zhu et al.   LANCET ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

(2009) Andrea Sartore-Bianchi et al.   PLoS One

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer

(2008) A. J. French et al.   CLINICAL CANCER RESEARCH

Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer

(2008) M. Wasif Saif et al.   Clinical Colorectal Cancer

Implications of EGFR PharmDx™ Kit for cetuximab eligibility

(2008) Christian Ensinger et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer

(2008) Francesco Graziano et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE